Test-retest reliability and smallest detectable change of the Bristol Impact of Hypermobility (BIoH) questionnaire

S. Palmer; S. Manns; F. Cramp; R. Lewis; E. M. Clark

doi:10.1016/j.msksp.2017.08.007

Test-retest reliability and smallest detectable change of the Bristol Impact of Hypermobility (BIoH) questionnaire

S. Palmer, S. Manns, F. Cramp, R. Lewis, E. M. Clark

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

37 Downloads (Pure)

Abstract

Objective The Bristol Impact of Hypermobility (BIoH) questionnaire is a patient-reported outcome measure developed in conjunction with adults with Joint Hypermobility Syndrome (JHS). It has demonstrated strong concurrent validity with the Short Form-36 (SF-36) physical component score but other psychometric properties have yet to be established. This study aimed to determine its test-retest reliability and smallest detectable change (SDC). Design A test-retest reliability study. Setting Participants were recruited from the Hypermobility Syndromes Association, a patient organisation in the United Kingdom. Patients Recruitment packs were sent to 1080 adults who had given permission to be contacted about research. Main outcome measures BIoH and SF-36 questionnaires were administered at baseline and repeated two weeks later. An 11-point global rating of change scale (−5 to +5) was also administered at two weeks. Test-retest analysis and calculation of the SDC was conducted on 'stable’ patients (defined as global rating of change −1 to +1). Results 462 responses were received. 233 patients reported a 'stable’ condition and were included in analysis (95% women; mean (SD) age 44.5 (13.9) years; BIoH score 223.6 (54.0)). The BIoH questionnaire demonstrated excellent test-retest reliability (ICC 0.923, 95% CI 0.900–0.940). The SDC was 42 points (equivalent to 19% of the mean baseline score). The SF-36 physical and mental component scores demonstrated poorer test-retest reliability and larger SDCs (as a proportion of the mean baseline scores). Conclusion The results provide further evidence of the potential of the BIoH questionnaire to underpin research and clinical practice for people with JHS.

Original language	English
Pages (from-to)	64-69
Number of pages	6
Journal	Musculoskeletal Science and Practice
Volume	32
Early online date	24 Aug 2017
DOIs	https://doi.org/10.1016/j.msksp.2017.08.007
Publication status	Published - Dec 2017
Externally published	Yes

Bibliographical note

NOTICE: this is the author’s version of a work that was accepted for publication in Musculoskeletal Science and Practice. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Musculoskeletal Science and Practice, 32, (2017)
DOI: 10.1016/j.msksp.2017.08.007

© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords

Benign hypermobility syndrome
Ehlers-danlos syndrome, hypermobility type
Questionnaire
Test-retest reliability

ASJC Scopus subject areas

Physical Therapy, Sports Therapy and Rehabilitation

Access to Document

10.1016/j.msksp.2017.08.007

Post-PrintAccepted author manuscript, 468 KBLicence: CC BY-NC-ND

Cite this

@article{372b49d662c241b988ea783bbcbab101,

title = "Test-retest reliability and smallest detectable change of the Bristol Impact of Hypermobility (BIoH) questionnaire",

abstract = "Objective The Bristol Impact of Hypermobility (BIoH) questionnaire is a patient-reported outcome measure developed in conjunction with adults with Joint Hypermobility Syndrome (JHS). It has demonstrated strong concurrent validity with the Short Form-36 (SF-36) physical component score but other psychometric properties have yet to be established. This study aimed to determine its test-retest reliability and smallest detectable change (SDC). Design A test-retest reliability study. Setting Participants were recruited from the Hypermobility Syndromes Association, a patient organisation in the United Kingdom. Patients Recruitment packs were sent to 1080 adults who had given permission to be contacted about research. Main outcome measures BIoH and SF-36 questionnaires were administered at baseline and repeated two weeks later. An 11-point global rating of change scale (−5 to +5) was also administered at two weeks. Test-retest analysis and calculation of the SDC was conducted on 'stable{\textquoteright} patients (defined as global rating of change −1 to +1). Results 462 responses were received. 233 patients reported a 'stable{\textquoteright} condition and were included in analysis (95% women; mean (SD) age 44.5 (13.9) years; BIoH score 223.6 (54.0)). The BIoH questionnaire demonstrated excellent test-retest reliability (ICC 0.923, 95% CI 0.900–0.940). The SDC was 42 points (equivalent to 19% of the mean baseline score). The SF-36 physical and mental component scores demonstrated poorer test-retest reliability and larger SDCs (as a proportion of the mean baseline scores). Conclusion The results provide further evidence of the potential of the BIoH questionnaire to underpin research and clinical practice for people with JHS.",

keywords = "Benign hypermobility syndrome, Ehlers-danlos syndrome, hypermobility type, Questionnaire, Test-retest reliability",

author = "S. Palmer and S. Manns and F. Cramp and R. Lewis and Clark, {E. M.}",

note = "NOTICE: this is the author{\textquoteright}s version of a work that was accepted for publication in Musculoskeletal Science and Practice. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Musculoskeletal Science and Practice, 32, (2017) DOI: 10.1016/j.msksp.2017.08.007 {\textcopyright} 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/",

year = "2017",

month = dec,

doi = "10.1016/j.msksp.2017.08.007",

language = "English",

volume = "32",

pages = "64--69",

journal = "Musculoskeletal Science and Practice",

issn = "2468-8630",

publisher = "Elsevier",

}

TY - JOUR

T1 - Test-retest reliability and smallest detectable change of the Bristol Impact of Hypermobility (BIoH) questionnaire

AU - Palmer, S.

AU - Manns, S.

AU - Cramp, F.

AU - Lewis, R.

AU - Clark, E. M.

N1 - NOTICE: this is the author’s version of a work that was accepted for publication in Musculoskeletal Science and Practice. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Musculoskeletal Science and Practice, 32, (2017) DOI: 10.1016/j.msksp.2017.08.007 © 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

PY - 2017/12

Y1 - 2017/12

N2 - Objective The Bristol Impact of Hypermobility (BIoH) questionnaire is a patient-reported outcome measure developed in conjunction with adults with Joint Hypermobility Syndrome (JHS). It has demonstrated strong concurrent validity with the Short Form-36 (SF-36) physical component score but other psychometric properties have yet to be established. This study aimed to determine its test-retest reliability and smallest detectable change (SDC). Design A test-retest reliability study. Setting Participants were recruited from the Hypermobility Syndromes Association, a patient organisation in the United Kingdom. Patients Recruitment packs were sent to 1080 adults who had given permission to be contacted about research. Main outcome measures BIoH and SF-36 questionnaires were administered at baseline and repeated two weeks later. An 11-point global rating of change scale (−5 to +5) was also administered at two weeks. Test-retest analysis and calculation of the SDC was conducted on 'stable’ patients (defined as global rating of change −1 to +1). Results 462 responses were received. 233 patients reported a 'stable’ condition and were included in analysis (95% women; mean (SD) age 44.5 (13.9) years; BIoH score 223.6 (54.0)). The BIoH questionnaire demonstrated excellent test-retest reliability (ICC 0.923, 95% CI 0.900–0.940). The SDC was 42 points (equivalent to 19% of the mean baseline score). The SF-36 physical and mental component scores demonstrated poorer test-retest reliability and larger SDCs (as a proportion of the mean baseline scores). Conclusion The results provide further evidence of the potential of the BIoH questionnaire to underpin research and clinical practice for people with JHS.

AB - Objective The Bristol Impact of Hypermobility (BIoH) questionnaire is a patient-reported outcome measure developed in conjunction with adults with Joint Hypermobility Syndrome (JHS). It has demonstrated strong concurrent validity with the Short Form-36 (SF-36) physical component score but other psychometric properties have yet to be established. This study aimed to determine its test-retest reliability and smallest detectable change (SDC). Design A test-retest reliability study. Setting Participants were recruited from the Hypermobility Syndromes Association, a patient organisation in the United Kingdom. Patients Recruitment packs were sent to 1080 adults who had given permission to be contacted about research. Main outcome measures BIoH and SF-36 questionnaires were administered at baseline and repeated two weeks later. An 11-point global rating of change scale (−5 to +5) was also administered at two weeks. Test-retest analysis and calculation of the SDC was conducted on 'stable’ patients (defined as global rating of change −1 to +1). Results 462 responses were received. 233 patients reported a 'stable’ condition and were included in analysis (95% women; mean (SD) age 44.5 (13.9) years; BIoH score 223.6 (54.0)). The BIoH questionnaire demonstrated excellent test-retest reliability (ICC 0.923, 95% CI 0.900–0.940). The SDC was 42 points (equivalent to 19% of the mean baseline score). The SF-36 physical and mental component scores demonstrated poorer test-retest reliability and larger SDCs (as a proportion of the mean baseline scores). Conclusion The results provide further evidence of the potential of the BIoH questionnaire to underpin research and clinical practice for people with JHS.

KW - Benign hypermobility syndrome

KW - Ehlers-danlos syndrome, hypermobility type

KW - Questionnaire

KW - Test-retest reliability

UR - http://www.scopus.com/inward/record.url?scp=85034060540&partnerID=8YFLogxK

U2 - 10.1016/j.msksp.2017.08.007

DO - 10.1016/j.msksp.2017.08.007

M3 - Article

C2 - 28881227

AN - SCOPUS:85034060540

SN - 2468-8630

VL - 32

SP - 64

EP - 69

JO - Musculoskeletal Science and Practice

JF - Musculoskeletal Science and Practice

ER -

Test-retest reliability and smallest detectable change of the Bristol Impact of Hypermobility (BIoH) questionnaire

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this